Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.

Yan, Shuang

Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo. [electronic resource] - Oncotarget Mar 2013 - 433-45 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Intramural

1949-2553

10.18632/oncotarget.930 doi


Animals
Apoptosis--drug effects
Caspases
Cell Cycle--drug effects
Cell Line
Cell Line, Tumor
Cell Survival--drug effects
Child
Dose-Response Relationship, Drug
Female
HEK293 Cells
Humans
Immunoblotting
Janus Kinase 2--antagonists & inhibitors
Mice
Mice, Nude
Mice, SCID
Neuroblastoma--drug therapy
Pyrazoles--administration & dosage
Pyrimidines--administration & dosage
STAT3 Transcription Factor--metabolism
Sarcoma--drug therapy
Signal Transduction--drug effects
Survival Analysis
Tumor Burden--drug effects
Xenograft Model Antitumor Assays